Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 79

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 79
---
abolism, extending biological half-life, and reducing toxicity [2]. These nanostructures circulate in the bloodstream for extended
periods and enable controlled drug release, thereby minimizing plasma fluctuations and associated adverse effects. Due to their nanoscale
size and their prolonged circulation in blood, they can potentially accumulate in tumors or inflamed tissues via the enhanced permeability
and retention (EPR) effect and improve cellular uptake. Studies have shown that nanoparticles (<200 nm) achieve greater cellular internalization
than microparticles (>1 µm), allowing for improved targeting while reducing off-target toxicity [2&3].

The advantages of liposomes as drug carriers
are well recognized. Over 20 liposomal and lipid-based formulations have received approval from the FDA and EMA, with many others in
clinical and preclinical development stages [4]. One of the earliest and most significant approvals was Doxil™, a liposomal formulation
of doxorubicin co-invented by Prof. Barenholz, and the first FDA-approved nano-drug.

More recently, lipid nanoparticles (LNPs)
have emerged as the leading non-viral delivery systems for nucleic acid-based therapeutics, including RNA interference (RNAi) and in
vitro transcribed (IVT) mRNA. Their role was central in the development and success of mRNA vaccines during the COVID-19 pandemic. These
include:

| ● | Pfizer-BioNTech (Comirnaty): Used LNPs to encapsulate       
 and deliver mRNA encoding the SARS-CoV-2 spike protein [5]. |

| ● | Moderna (Spikevax): Similarly relied on LNP technology 
 for mRNA stabilization and delivery [6].               |

| ● | Arcturus: Developed an mRNA vaccine platform using                                         
 LNPs, demonstrating the broader trend toward LNP adoption in mRNA vaccine development [7]. |

The demonstrated success of using LNPs as
efficient drug delivery means in COVID-19 vaccines has fueled expanded research into their application in gene therapy, oncology, and
other infectious diseases [8].

Our proprietary technology builds on the same
principles that made Doxil®, the first FDA-approved Nanomedicine using liposomal drug delivery, a success. We intend to apply these
principles to treat infectious diseases and cancer by encapsulating potent therapeutics in proven lipid-based particles, such as those
used in Doxil®. By encapsulating potent therapeutics, our approach is intended to enable controlled release, improve biod